 |
 |
  |
| Lou is an industry veteran and is focused
on identifying emerging biopharmaceutical, device and platform technology
companies. Lou sits on the Boards of Ascenta Therapeutics, diaDexus,
Horizon Therapeutics, Orexigen Therapeutics, SGX Pharmaceuticals,
Sonexa and Zogenix. He is responsible for ScaleVP's investments in
Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle
Genetics (NASDAQ: SGEN), and Somaxon (NASDAQ: SOMX).
Lou joined Scale Venture Partners in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide, and was responsible for the discovery of Gilead's novel thrombin aptamer. Previous to Gilead, he was a research associate at Genentech. Lou holds an MBA from California State University, San Francisco and a BS in Biology from California State University, Chico. |
|
  |
